Metropolis Healthcare Ltd

Q1 FY27Healthcare Services

Metropolis Healthcare Ltd Q1 FY27 Results & Concall Highlights: Revenue, Margins & Order Book

Q1 FY27 earnings call: what management guided on revenue, margins and order book.

Price₹589

Market cap₹11.6K Cr

P/E55.5

Published6 Sept 2026

What the Q1 FY27 call signalled

2 of 3 strong

RevenueRank 3

MarginRank 1

CapexYes

Not discussed on this call: fundraise, order book.

The short version

North India currently contributes 18% to revenue and is expected to grow faster, potentially increasing contribution to 25% in the next few years. Metropolis aims for volume-led growth driven by expansion in Tier 2 and Tier 3 towns, specialty testing, and TruHealth services.

From Metropolis Healthcare Ltd's Q1 FY27 earnings-call transcript · updated 6 Sept 2026.

Revenue & Sales Performance

Rank 3

North India currently contributes 18% to revenue and is expected to grow faster, potentially increasing contribution to 25% in the next few years.
East India currently 6%, with limited investment so far; future investments may increase contribution.
Overall revenue growth is volume-driven, with expansion focused on Tier 2 and Tier 3 towns through increased centers without adding more labs, improving penetration and customer reach.
Specialty and genomics segments are key growth drivers, expecting disproportionate growth due to hospital expansions in Tier 2/3 towns.
Addition of 1,000 more centers in 3 years planned, including 100 mini hubs offering radiology and allied services, enhancing service portfolio and customer engagement.
TruHealth wellness portfolio to grow from 18% to 25% contribution.
Home collection services (~11-12% revenue) have substantial growth potential.
Corporate and insurance segments to drive increased utilization at mini hubs.
Company targets a 14-15% revenue growth guidance, with potential for acceleration beyond historical 12-13% CAGR.

Profitability & Margins

Metropolis aims for volume-led growth driven by expansion in Tier 2 and Tier 3 towns, specialty testing, and TruHealth services.
EBITDA margin target is to improve from 24.4% to 27%-28% over the next 2-3 years through better mix, productivity, and network utilization.
FY27 growth guidance is 14%-15% without price increases; Q1 FY27 saw 17% growth indicating acceleration.
Operating leverage expected from increasing center-to-lab ratio, digitalization, and automation.
Long-term margin expansion possible with economies of scale but balanced with ongoing reinvestments in technology and new centers.
Acquisitions remain an integral growth element but will be pursued with price discipline.
EPS growth should mirror the combination of volume expansion, margin improvement, and efficient capital allocation.
International business contributes less than 10% revenue; focus remains on densifying Indian business.

See what Metropolis Healthcare Ltd said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

Yes

Metropolis is evaluating two models for radiology center expansion: capex and opex.
If investing via capex, the approximate cost per center is INR 35-40 lakhs for equipment like X-ray, ultrasound, treadmill, DEXA scan.
Plan to experiment with 50 centers in the first year, followed by another 50 next year, focusing on location and service quality.
The business prioritizes disciplined capital allocation with a capital-light approach overall.
Ongoing reinvestments in technology, digital automation, AI, and expansion of labs and centers ensure long-term relevance and growth.
They are investing in allied healthcare services and specialty portfolios, possibly via asset-light models and subscription programs.
M&A remains a strategic capital deployment area, focusing on acquiring and turning around suboptimal but scalable diagnostic businesses.
Expected steady-state margins with reinvestments to expand industry size over 10-20 years.

Fundraising & Capital Structure

There is no explicit mention of any current or near-future fundraising through debt or equity in the provided pages.
The company emphasizes disciplined capital allocation and intends to remain capital investment light.
Investments planned are mainly for expanding centers and entering new service areas like radiology with manageable capex (INR35-40 lakhs per mini-hub).
No indication of reliance on external equity or debt for financing; international operations are self-sustaining and do not receive capital from Indian operations.
Focus remains on generating cash internally through operational performance improvements and maintaining steady-state margins.
The strategy involves reinvesting earnings for growth rather than raising new external capital at this point.

See what Metropolis Healthcare Ltd said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

The provided transcript of Metropolis Healthcare Limited’s Investors & Analyst Meet dated August 27, 2026, does not explicitly mention the current or expected order book or pending orders. The discussion primarily covers topics such as: - Geographic growth focus (North India, East India) - Business strategies including expansion of collection centers and radiology services - Revenue mix (B2B vs B2C) - M&A strategy and consolidation approach - Financial guidance (14-15% growth without price increase, Q1 at 17%) - Operational metrics like number of centers, tests, and doctor referrals - Strategic initiatives beyond diagnostics No specific data on order book or pending orders is disclosed in the transcript.

How does Metropolis Healthcare Ltd rank vs peers in Healthcare Services?

Pro feature

ThisMetropolis Healthcare Ltd

Rev 3Mar 1

See where Metropolis Healthcare Ltd sits in Healthcare ServicesSee which companies these are, and every other name in the sector.Open rankings

Metropolis Healthcare Ltd — Quarterly revenue & net profit

Revenue Net profit

Dec 2024

Mar 2025

Jun 2025

Sep 2025

Dec 2025

Mar 2026

Reported quarterly figures (₹ Cr). Latest: revenue ₹425 Cr, net profit ₹51 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

What Metropolis Healt's management said in earlier quarters

Others in Healthcare Services this season

Apollo Hospitals (Q1 FY27)
IP volume growth for established units guided at roughly 7% to 8%. Key concall takeaways from Apollo Hospitals Enterprise Ltd's Q1 FY27 earnings call — and how…
Health X Platform (Q1 FY27)
July monthly revenue stood at INR 150+ crores, indicating strong growth momentum. Key concall takeaways from Health X Platform Ltd's Q1 FY27 earnings call…
Shalby (Q1 FY27)
Shalby MedTech showed strong revenue growth: ₹47 crores in Q1 FY27, a 53% YoY increase. Key concall takeaways from Shalby Ltd's Q1 FY27 earnings call — and how…
Nephrocare Health Services (Q1 FY27)
International operations contribute around 45% of revenue, reflecting their growing importance in overall growth. Key concall takeaways from Nephrocare Health…

Compare:vs Apollo Hospitals vs Max Healthcare vs Fortis Health.

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Frequently Asked Questions

What were Metropolis Healthcare Ltd Q1 FY27 results?

What is Metropolis Healthcare Ltd share price analysis?

Metropolis Healthcare Ltd currently shows a below-average growth signal. The stock trades at a P/E of 55.5 with a market cap of ₹11,550 Cr. Investors should review the full earnings analysis for detailed insights.

Is Metropolis Healthcare Ltd planning capital expenditure?

Metropolis is evaluating two models for radiology center expansion: capex and opex.

Keep Metropolis Healthcare Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.